140 related articles for article (PubMed ID: 32683206)
1. Genetic association of gemcitabine/carboplatin-induced leukopenia and neutropenia in non-small cell lung cancer patients using whole-exome sequencing.
Svedberg A; Björn N; Sigurgeirsson B; Pradhananga S; Brandén E; Koyi H; Lewensohn R; De Petris L; Apellániz-Ruiz M; Rodríguez-Antona C; Lundeberg J; Gréen H
Lung Cancer; 2020 Sep; 147():106-114. PubMed ID: 32683206
[TBL] [Abstract][Full Text] [Related]
2. Using Whole-Exome Sequencing to Identify Genetic Markers for Carboplatin and Gemcitabine-Induced Toxicities.
Gréen H; Hasmats J; Kupershmidt I; Edsgärd D; de Petris L; Lewensohn R; Blackhall F; Vikingsson S; Besse B; Lindgren A; Brandén E; Koyi H; Peterson C; Lundeberg J
Clin Cancer Res; 2016 Jan; 22(2):366-73. PubMed ID: 26378035
[TBL] [Abstract][Full Text] [Related]
3. Genes and variants in hematopoiesis-related pathways are associated with gemcitabine/carboplatin-induced thrombocytopenia.
Björn N; Sigurgeirsson B; Svedberg A; Pradhananga S; Brandén E; Koyi H; Lewensohn R; de Petris L; Apellániz-Ruiz M; Rodríguez-Antona C; Lundeberg J; Gréen H
Pharmacogenomics J; 2020 Apr; 20(2):179-191. PubMed ID: 31616045
[TBL] [Abstract][Full Text] [Related]
4. Whole-genome sequencing and gene network modules predict gemcitabine/carboplatin-induced myelosuppression in non-small cell lung cancer patients.
Björn N; Badam TVS; Spalinskas R; Brandén E; Koyi H; Lewensohn R; De Petris L; Lubovac-Pilav Z; Sahlén P; Lundeberg J; Gustafsson M; Gréen H
NPJ Syst Biol Appl; 2020 Aug; 6(1):25. PubMed ID: 32839457
[TBL] [Abstract][Full Text] [Related]
5. The association of four genetic variants with myelosuppression in gemcitabine-treated Japanese is not evident in gemcitabine/carboplatin-treated Swedes.
Björn N; Jakobsen I; Udagawa C; Brandén E; Koyi H; Lewensohn R; De Petris L; Zembutsu H; Gréen H
Basic Clin Pharmacol Toxicol; 2022 Apr; 130(4):513-521. PubMed ID: 35132780
[TBL] [Abstract][Full Text] [Related]
6. A genome-wide association study identifies four genetic markers for hematological toxicities in cancer patients receiving gemcitabine therapy.
Kiyotani K; Uno S; Mushiroda T; Takahashi A; Kubo M; Mitsuhata N; Ina S; Kihara C; Kimura Y; Yamaue H; Hirata K; Nakamura Y; Zembutsu H
Pharmacogenet Genomics; 2012 Apr; 22(4):229-35. PubMed ID: 22293537
[TBL] [Abstract][Full Text] [Related]
7. A phase I dose escalation study of biweekly gemcitabine and carboplatin in completely resected stage IB-IIIA nonsmall cell lung cancer.
Tomizawa Y; Ishihara S; Iijima H; Imai H; Sato K; Yatomi M; Iwasaki Y; Yamada H; Kobayashi G; Ishida E; Inoue T; Aoki H; Watanabe S; Kawashima O; Mori M; Saito R
Am J Clin Oncol; 2007 Oct; 30(5):498-502. PubMed ID: 17921710
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of gemcitabine and carboplatin in advanced non-small cell lung carcinoma.
Gajra A; Mehdi SA; Kirshner J; Newman N; Graziano SL
Lung Cancer; 2001 May; 32(2):189-96. PubMed ID: 11325490
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase II study of two schedules of carboplatin and gemcitabine for stage IIIB and IV advanced non-small cell lung cancer (JACCRO LC-01 study).
Imamura F; Nishio M; Noro R; Tsuboi M; Ikeda N; Inoue A; Ohsaki Y; Kimura Y; Nishino K; Uchida J; Horai T
Chemotherapy; 2011; 57(4):357-62. PubMed ID: 21912118
[TBL] [Abstract][Full Text] [Related]
10. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer.
Grønberg BH; Bremnes RM; Fløtten O; Amundsen T; Brunsvig PF; Hjelde HH; Kaasa S; von Plessen C; Stornes F; Tollåli T; Wammer F; Aasebø U; Sundstrøm S
J Clin Oncol; 2009 Jul; 27(19):3217-24. PubMed ID: 19433683
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II trial of paclitaxel by 1-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced nonsmall cell lung carcinoma.
Hainsworth JD; Burris HA; Erland JB; Morrissey LH; Meluch AA; Kalman LA; Hon JK; Scullin DC; Smith SW; Greco FA
Cancer; 1999 Mar; 85(6):1269-76. PubMed ID: 10189131
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide association study of chemotherapeutic agent-induced severe neutropenia/leucopenia for patients in Biobank Japan.
Low SK; Chung S; Takahashi A; Zembutsu H; Mushiroda T; Kubo M; Nakamura Y
Cancer Sci; 2013 Aug; 104(8):1074-82. PubMed ID: 23648065
[TBL] [Abstract][Full Text] [Related]
13. Phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non-small-cell lung cancer.
Iaffaioli RV; Tortoriello A; Facchini G; Caponigro F; Gentile M; Marzano N; Gravina A; Dimitri P; Costagliola G; Ferraro A; Ferrante G; De Marino V; Illiano A
J Clin Oncol; 1999 Mar; 17(3):921-6. PubMed ID: 10071285
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of carboplatin plus gemcitabine in advanced non-small-cell lung cancer (NSCLC): a hoosier oncology group study.
Ng EW; Sandler AB; Robinson L; Einhorn LH
Am J Clin Oncol; 1999 Dec; 22(6):550-3. PubMed ID: 10597737
[TBL] [Abstract][Full Text] [Related]
15. Biweekly combination therapy with gemcitabine and carboplatin compared with gemcitabine monotherapy in elderly patients with advanced non-small-cell lung cancer: a randomized, phase-II study.
Kusagaya H; Inui N; Karayama M; Nakamura Y; Kuroishi S; Yokomura K; Toyoshima M; Shirai T; Masuda M; Yamada T; Yasuda K; Suda T; Chida K
Lung Cancer; 2012 Sep; 77(3):550-5. PubMed ID: 22705118
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of biweekly gemcitabine and carboplatin in completely resected stage IB-IIIA non-small cell lung cancer.
Sakurai R; Tomizawa Y; Yoshii A; Miura Y; Tsurumaki H; Kaira K; Sunaga N; Kawashima O; Hisada T; Yamada M; Saito R
Cancer Chemother Pharmacol; 2018 Jan; 81(1):103-109. PubMed ID: 29124327
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel and carboplatin in combination with gemcitabine: a phase I-II trial in patients with advanced non-small-cell lung cancer. Gruppo Studio Tumori Polmonari Veneto (GSTPV).
Favaretto A; Ceresoli GL; Paccagnella A; Barbieri F; Bearz A; Ghiotto C; Oniga F; Schiavon S; Frustaci S; Villa E
Ann Oncol; 2000 Nov; 11(11):1421-6. PubMed ID: 11142482
[TBL] [Abstract][Full Text] [Related]
18. Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial.
Tan AR; Wright GS; Thummala AR; Danso MA; Popovic L; Pluard TJ; Han HS; Vojnović Ž; Vasev N; Ma L; Richards DA; Wilks ST; Milenković D; Yang Z; Antal JM; Morris SR; O'Shaughnessy J
Lancet Oncol; 2019 Nov; 20(11):1587-1601. PubMed ID: 31575503
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of gemcitabine and carboplatin in metastatic non-small-cell lung cancer: a Groupe Français de Pneumo-Cancérologie Study.
Thomas P; Robinet G; Ferri-Dessens RM; Léna H; Gouva S; Vernejoux JM; Kleisbauer JP
Lung Cancer; 2002 May; 36(2):191-8. PubMed ID: 11955654
[TBL] [Abstract][Full Text] [Related]
20. A novel triplet regimen with paclitaxel, carboplatin and gemcitabine (PACCAGE) as induction chemotherapy for locally advanced unresectable non small cell lung cancer (NSCLC).
Schallier D; Neyns B; Fontaine C; Steene JV; De Mey J; Meysman M; De Grève J
Lung Cancer; 2007 May; 56(2):247-54. PubMed ID: 17337086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
